The stock of Achilles Therapeutics Plc ADR (ACHL) has seen a 2.16% increase in the past week, with a 2.90% gain in the past month, and a 35.24% flourish in the past quarter. The volatility ratio for the week is 1.52%, and the volatility levels for the past 30 days are at 1.37% for ACHL. The simple moving average for the last 20 days is 2.43% for ACHL stock, with a simple moving average of 41.94% for the last 200 days.
Is It Worth Investing in Achilles Therapeutics Plc ADR (NASDAQ: ACHL) Right Now?
The 36-month beta value for ACHL is also noteworthy at 1.17. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ACHL is 37.95M, and at present, short sellers hold a 1.26% of that float. The average trading volume of ACHL on March 14, 2025 was 1.18M shares.
ACHL) stock’s latest price update
The stock price of Achilles Therapeutics Plc ADR (NASDAQ: ACHL) has surged by 2.16 when compared to previous closing price of 1.39, but the company has seen a 2.16% gain in its stock price over the last five trading sessions. globenewswire.com reported 2024-12-24 that – Proprietary data and samples from TRACERx and Achilles’ Material Acquisition Platform (MAP) will be transferred to AstraZeneca under the Transaction –
Analysts’ Opinion of ACHL
Many brokerage firms have already submitted their reports for ACHL stocks, with Piper Sandler repeating the rating for ACHL by listing it as a “Neutral.” The predicted price for ACHL in the upcoming period, according to Piper Sandler is $2 based on the research report published on April 05, 2024 of the previous year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see ACHL reach a price target of $25. The rating they have provided for ACHL stocks is “Overweight” according to the report published on April 26th, 2021.
Oppenheimer gave a rating of “Outperform” to ACHL, setting the target price at $23 in the report published on April 26th of the previous year.
ACHL Trading at 11.12% from the 50-Day Moving Average
After a stumble in the market that brought ACHL to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 0.71% of gains for the given period.
Volatility was left at 1.37%, however, over the last 30 days, the volatility rate increased by 1.52%, as shares surge +2.90% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +25.66% upper at present.
During the last 5 trading sessions, ACHL rose by +2.16%, which changed the moving average for the period of 200-days by +58.43% in comparison to the 20-day moving average, which settled at $1.3863. In addition, Achilles Therapeutics Plc ADR saw 24.56% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ACHL starting from Coutts Robert William, who proposed sale 4,168 shares at the price of $1.20 back on Mar 03 ’25. After this action, Coutts Robert William now owns shares of Achilles Therapeutics Plc ADR, valued at $5,006 using the latest closing price.
Ali Iraj, the Director of Achilles Therapeutics Plc ADR, proposed sale 9,376 shares at $1.22 during a trade that took place back on Mar 03 ’25, which means that Ali Iraj is holding shares at $11,466 based on the most recent closing price.
Stock Fundamentals for ACHL
The total capital return value is set at -0.69. Equity return is now at value -52.41, with -45.13 for asset returns.
Based on Achilles Therapeutics Plc ADR (ACHL), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -8.47.
Currently, EBITDA for the company is -70.44 million with net debt to EBITDA at 1.2. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.04.
Conclusion
In summary, Achilles Therapeutics Plc ADR (ACHL) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
